Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
Business news for the stock market

Biofrontera AG: Biofrontera obtains notice of allowance for Australian patent on innovative PDT treatment protocol

Leverkusen, Germany (pta/13.07.2022/14:55) -

Biofrontera AG (FSE: B8F, US-OTC: BFAGY), an international biopharmaceutical company, announces that the Australian Patent Office (IP Australia) has granted the patent "Photodynamic therapy comprising two light exposures at different wavelengths" (AU 2018/437303B2) after the opposition period expired without a "notice of opposition" being received by the Office. The patent, filed by Biofrontera Bioscience GmbH, protects a number of innovations related to new illumination protocols for the treatment of skin diseases with photodynamic therapy (PDT). It covers a treatment protocol that combines the lower pain of daylight PDT with the higher cure rates and lower recurrence rates of conventional therapy. The treatment method uses a photosensitizer in combination with two light exposures of different wavelengths and exposure durations. The application of a photosensitizer is followed first by a longer exposure to a broadband light (e.g., sunlight or light from an appropriate artificial light source) or blue light, followed by a subsequent, much shorter exposure to narrowband red light (e.g., light from Biofrontera's RhodoLED® lamps).

In the claims of this patent, this innovative illumination approach is linked to the performance of PDT with a drug containing a photosensitizer or its precursor. In this respect, the use of the illumination combination protected in this patent also protects Biofrontera's drug Ameluz®.

"The granting of the patent shows once again that Biofrontera's research and development is finding innovative approaches to improve the treatment of skin diseases worldwide and that it has become an expert in PDT over the last 10 years. We are convinced that the painless application of Ameluz®-PDT without reducing its effectiveness will make a major contribution to skin health," comments Biofrontera's Executive Board member Ludwig Lutter on the granting of the patent in Australia as another building block in establishing this treatment option worldwide.


About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY).

Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "predict", "estimate" and "intend", among others. Such forward-looking statements are based on current estimates and assumptions made by Biofrontera AG's management to the best of its knowledge and belief, which in their opinion are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the company or industry to be materially different from any future results, financial condition, performance or achievements expressed or implied by such forward-looking statements. No undue reliance should be placed on such statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements.


Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Contact Person: Investor Relations
Phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate
Other Stock Exchanges: US OTC